Lilly/BI biosimilar Lantus approved in Europe
This article was originally published in Scrip
Executive Summary
Sanofi's blockbuster long-lasting insulin, Lantus, faces market erosion in Europe following the approval there of a biosimilar version from Lilly and Boehringer Ingelheim. Their insulin glargine product, with the provisional brand name Abasria, is the first insulin treatment to be approved through the European Medicines Agency's biosimilar pathway.
You may also be interested in...
Boehringer Taps Gubra For Early-Stage Obesity Deal
Boehringer Ingelheim has signed a collaboration with Denmark-based Gubra focusing on the development of peptides to treat obesity, with Gubra to receive up to €250m in upfront and potential milestone payments.
Top-Selling Drugs 2022: Strong Growth In Blockbuster Ranks
COVID-19 products contributed almost a third to the global revenues from the top 20 best-selling drugs in 2022. However, strong growth was also seen for drugs across categories from immunology and cancer to HIV and cardiometabolic.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.